Browse the evidence

SGLT2 inhibitors provide modest but sustained weight loss and blood pressure reduction, and synergize with other anti-obesity medications.

SGLT2 inhibitors offer modest weight and blood pressure benefits. They are best used in combination with other treatments (like GLP-1 RAs) to synergize benefits, rather than as a standalone primary therapy for obesity-related hypertension.

Supplementation with 5g/day of 2'-fucosyllactose (2'-FL) for 6 weeks increases Bifidobacterium abundance in older adults, which is associated with elevated HDL cholesterol, fasting insulin, and FGF21 levels.

If you are an older adult, consuming 5 grams of 2'-fucosyllactose daily for 6 weeks may boost beneficial gut bacteria (Bifidobacterium) and improve metabolic markers like HDL cholesterol and insulin levels. This suggests that prebiotics designed for infants might offer health benefits for aging adults by modulating the gut microbiome.

The metabolic benefits of 2'-fucosyllactose (increased HDL, insulin, FGF21) are contingent on the subject being a 'responder' who experiences a bloom in Bifidobacterium abundance.

Not everyone will benefit from 2'-fucosyllactose. If you don't have Bifidobacterium in your gut, you might not see the metabolic improvements (like better HDL or insulin sensitivity) that others do. Testing your microbiome might help predict if this supplement is right for you.

Tirzepatide should be used in combination with CPAP for patients with severe OSA, as the drug takes 6-12 months to significantly reduce AHI, leaving patients at risk during the interim.

If you have severe OSA, do not stop CPAP when starting tirzepatide. The drug takes 6-12 months to significantly reduce your apnea. Use CPAP nightly during this period to protect your heart and safety. After a year, if your AHI has dropped significantly, you and your doctor can discuss tapering off CPAP.

GLP-1 receptor agonist-mediated weight loss causes facial volume loss and skin laxity that mimics advanced aging, a phenomenon termed 'Ozempic face,' which is managed through volume restoration (fillers/fat grafting) or skin tightening procedures.

If you are using GLP-1 medications like Ozempic or Wegovy, be aware that rapid weight loss can lead to facial volume loss and skin laxity, making you look older. This is a known side effect of the weight loss itself, not necessarily a unique drug effect on facial fat. You can manage this with fillers, fat grafting, or skin tightening procedures. Discuss these risks with your provider before starting treatment.

Discontinuation of GLP-1 receptor agonists leads to significant weight regain (up to two-thirds of lost weight) and reversal of cardiometabolic improvements.

If you stop taking GLP-1 medications, you are likely to regain a significant portion of the weight you lost. Long-term use is often necessary to maintain weight loss and metabolic benefits. Discuss a long-term plan with your provider before stopping.

Continuing tirzepatide treatment beyond 12 weeks allows the vast majority (90%) of 'late responders' (those with <5% weight loss at Week 12) to achieve clinically meaningful weight reduction (≥5%) by Week 72.

If you are taking tirzepatide and haven't lost significant weight in the first 3 months, do not stop. Your dose is likely still being increased. Most people who seem like 'non-responders' early on will achieve meaningful weight loss if they stay on the medication until they reach their maximum dose (around 20-25 weeks).

Obesity and weight gain drive regional sympathetic nervous system activation, which initiates and worsens cardiometabolic risk factors including hypertension, insulin resistance, and dyslipidemia.

If you are overweight, your body's stress response (sympathetic nervous system) is likely overactive, contributing to high blood pressure and insulin resistance. This is a biological response to excess fat, not just a lack of willpower. Addressing the underlying metabolic drivers (like insulin resistance) is key to reducing this sympathetic overdrive.

GLP-1 receptor agonists reduce cardiovascular risk and promote weight loss, but they cause a transient increase in heart rate that is independent of sympathetic nervous system activation.

GLP-1 medications like Ozempic or Wegovy help with weight loss and heart health. They might slightly increase your resting heart rate, but this is a direct effect on the heart's electrical system, not stress, and does not negate the heart benefits.

Hypoglossal nerve stimulation (HGNS) significantly reduces apnea-hypopnea index (AHI) and improves sleep quality in adults with moderate-to-severe OSA who are intolerant of or fail CPAP therapy.

If you have moderate-to-severe sleep apnea and cannot tolerate CPAP, ask your doctor about hypoglossal nerve stimulation (HGNS). It involves a small implant that stimulates the nerve controlling your tongue to keep your airway open during sleep. It is not for everyone (e.g., severe obesity or specific anatomical issues may exclude you), but for eligible patients, it significantly reduces apnea events and improves sleep quality without the daily hassle of a CPAP machine.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce AHI and body weight in patients with obesity and moderate-to-severe OSA, with tirzepatide showing superior efficacy compared to other GLP-1 RAs.

If you have obesity and moderate-to-severe sleep apnea, ask your doctor about GLP-1 receptor agonists like tirzepatide (Zepbound). These medications help with weight loss and have been shown to significantly reduce the severity of sleep apnea. They are taken as a weekly injection and can have gastrointestinal side effects, but these often improve over time. This treatment is particularly beneficial for those whose OSA is driven by obesity.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) significantly reduce energy intake and hunger while improving satiety, but current clinical trials largely fail to report detailed dietary quality or food intake data, limiting the ability to tailor nutritional counseling.

GLP-1 medications like semaglutide and tirzepatide effectively reduce hunger and energy intake, leading to significant weight loss. However, because most clinical trials do not report detailed dietary quality, patients should proactively track their food intake and nutrient quality to ensure long-term success and prevent nutritional deficiencies, as the drug alone does not guarantee healthy eating habits.

Short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate promote satiety and improve metabolic health by stimulating GLP-1 and PYY secretion and modulating gut-brain signaling, despite inconsistent fecal level measurements in obesity.

Consume fiber-rich foods to support SCFA production. This supports satiety hormones (GLP-1/PYY) and gut health, even if direct measurement of SCFAs is not feasible.

Elevated circulating branched-chain amino acids (BCAAs) and imidazole propionate (IMP) are causally linked to insulin resistance and type 2 diabetes, serving as predictive biomarkers years before clinical onset.

Monitor metabolic health through regular check-ups. Dietary patterns that improve insulin sensitivity (e.g., balanced macronutrients, fiber) can help manage BCAA and IMP levels.

Once-daily oral semaglutide (up to 14 mg) reduces systolic blood pressure and total cholesterol in patients with type 2 diabetes.

If you have Type 2 Diabetes, adding oral semaglutide to your current regimen can help lower your systolic blood pressure and total cholesterol. The standard protocol starts at a low dose (3 mg) and increases to 14 mg daily over two months to minimize side effects. This oral option offers cardiovascular protection similar to the injectable version, which may be easier for you to stick with long-term.

Oral semaglutide consistently reduces LDL cholesterol and triglycerides, but its effect on HDL cholesterol is inconsistent and clinically insignificant.

Oral semaglutide helps lower 'bad' cholesterol (LDL) and triglycerides in most patients with Type 2 Diabetes. However, do not expect it to reliably raise 'good' cholesterol (HDL), as studies show mixed and clinically insignificant results for HDL changes.

GIP receptor (GIPR) antagonism enhances the weight-loss efficacy of GLP-1 receptor agonists by removing an inhibitory tone on central nervous system (CNS) satiety circuits, specifically within hindbrain GABAergic neurons.

If you are using a GLP-1 medication (like semaglutide or liraglutide) and experiencing significant side effects like nausea without sufficient weight loss, newer therapies that block the GIP receptor (antagonism) while activating GLP-1 may be more effective and tolerable. This works by removing a natural 'brake' on your brain's satiety signals, allowing the medication to work more efficiently.

GLP-1 receptor agonists (semaglutide and tirzepatide) produce highly heterogeneous weight loss outcomes, with 'super responders' achieving >15% body weight loss while 'minimal responders' achieve <5%, driven by distinct pre-treatment clinical phenotypes rather than uniform biological response.

If you are taking a GLP-1 medication like Ozempic or Mounjaro, understand that your weight loss outcome is not guaranteed to be 'super' (>15% loss). Your pre-existing health conditions (like sleep apnea, psoriasis, or fibromyalgia) may predict how well you respond. Focus on the health benefits of even moderate weight loss (5-15%) rather than comparing yourself to 'super responder' statistics, as individual biology plays a massive role in the final result.

Pre-treatment clinical phenotypes, specifically the presence or absence of certain comorbidities, are strongly associated with the likelihood of being a 'super responder' to specific GLP-1RA brands.

Your existing health conditions might predict how well a specific weight-loss drug will work for you. For example, those without fibromyalgia or osteoarthritis might respond better to Zepbound, while those with psoriasis might respond better to Wegovy. Discuss your full medical history with your provider to help select the most appropriate GLP-1RA.

Tirzepatide (Zepbound/Mounjaro) is associated with a higher proportion of 'super responders' (>15% weight loss) compared to semaglutide (Ozempic/Wegovy) in real-world settings.

If you are choosing between GLP-1 medications, tirzepatide (Zepbound/Mounjaro) may offer a higher probability of 'super response' (>15% weight loss) compared to semaglutide (Ozempic/Wegovy). However, individual response varies, and your specific health profile should guide the choice.

GLP-1 receptor agonists (GLP-1RAs) treat obesity by activating central and peripheral GLP-1 receptors to increase satiety, delay gastric emptying, and modulate energy expenditure, resulting in significant weight loss.

GLP-1 receptor agonists are a class of medications that mimic a gut hormone to signal fullness to the brain and slow digestion. They are prescribed for obesity and type 2 diabetes. Common examples include Semaglutide (Ozempic/Wegovy) and Liraglutide (Saxenda). These drugs require a prescription and often involve starting at a low dose to manage side effects like nausea. They are part of a long-term management strategy for obesity, not a quick fix.

GLP-1 receptor agonists (GLP-1 RAs) are displacing bariatric surgery as the primary obesity treatment in the US, evidenced by a 1451% increase in GLP-1 RA use and a 65% decline in bariatric surgery procedures.

GLP-1 medications are becoming the dominant obesity treatment in the US, largely replacing bariatric surgery in utilization trends. However, surgery remains a crucial option for severe obesity due to its durability, especially if GLP-1 medications are discontinued. Patients should discuss long-term adherence and potential side effects with their providers.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates rapidly increasing real-world utilization as both a glucose-lowering medication and an anti-obesity medication in patients with chronic kidney disease (CKD), with initiators showing high rates of obesity and morbid obesity.

For patients with CKD, tirzepatide is increasingly being used to manage both blood sugar and weight. Real-world data indicates that doctors are prescribing it more frequently, especially for those with obesity. While clinical trials have limited CKD representation, real-world usage is high and growing.

Dual GLP-1/GIP receptor agonism (e.g., tirzepatide) produces synergistic body weight loss compared to selective GLP-1 receptor agonists, a mechanism dependent on the interaction of signals in neurotensin-expressing neurons (Nts CeA) within the central amygdala.

Dual GLP-1/GIP medications (like tirzepatide) are more effective for weight loss than GLP-1-only drugs because they activate a specific brain pathway (neurotensin neurons in the central amygdala) that GLP-1 drugs alone do not fully engage. This biological synergy is the reason for their superior efficacy, not just better stomach tolerance.